风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

除了症状表现之外，是否有检验指标可以准确判断免疫抑制剂该不该停用?

2021-10-09 MedSci原创 MedSci原创

免疫免疫抑制剂
关注

免疫抑制人群的感染的判断和治疗-问题1

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1986153, encodeId=1eb319861534b, content=<a href='/topic/show?id=fe4162584ed' target=_blank style='color:#2F92EE;'>#检验指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62584, encryptionId=fe4162584ed, topicName=检验指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jul 07 17:16:38 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852771, encodeId=62dc1852e71fb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Sep 09 14:16:38 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286305, encodeId=072312863056b, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Oct 11 02:16:38 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058972, encodeId=c39910589e29b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73be5472067, createdName=MYR哈哈哈哈, createdTime=Sat Oct 09 15:03:58 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058947, encodeId=bff5105894e27, content=学习了，不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Oct 09 13:20:27 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058909, encodeId=de571058909d9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211110/a1093f9556844f29afef12001f490cf8/3c85211d07a6410dbddb9b338d63913f.jpg, createdBy=d1c85308255, createdName=陈弦, createdTime=Sat Oct 09 11:34:38 CST 2021, time=2021-10-09, status=1, ipAttribution=)]
    2022-07-07 liao1619

    #检验指标#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1986153, encodeId=1eb319861534b, content=<a href='/topic/show?id=fe4162584ed' target=_blank style='color:#2F92EE;'>#检验指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62584, encryptionId=fe4162584ed, topicName=检验指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jul 07 17:16:38 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852771, encodeId=62dc1852e71fb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Sep 09 14:16:38 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286305, encodeId=072312863056b, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Oct 11 02:16:38 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058972, encodeId=c39910589e29b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73be5472067, createdName=MYR哈哈哈哈, createdTime=Sat Oct 09 15:03:58 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058947, encodeId=bff5105894e27, content=学习了，不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Oct 09 13:20:27 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058909, encodeId=de571058909d9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211110/a1093f9556844f29afef12001f490cf8/3c85211d07a6410dbddb9b338d63913f.jpg, createdBy=d1c85308255, createdName=陈弦, createdTime=Sat Oct 09 11:34:38 CST 2021, time=2021-10-09, status=1, ipAttribution=)]
    2022-09-09 jklm09

    #抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1986153, encodeId=1eb319861534b, content=<a href='/topic/show?id=fe4162584ed' target=_blank style='color:#2F92EE;'>#检验指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62584, encryptionId=fe4162584ed, topicName=检验指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jul 07 17:16:38 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852771, encodeId=62dc1852e71fb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Sep 09 14:16:38 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286305, encodeId=072312863056b, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Oct 11 02:16:38 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058972, encodeId=c39910589e29b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73be5472067, createdName=MYR哈哈哈哈, createdTime=Sat Oct 09 15:03:58 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058947, encodeId=bff5105894e27, content=学习了，不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Oct 09 13:20:27 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058909, encodeId=de571058909d9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211110/a1093f9556844f29afef12001f490cf8/3c85211d07a6410dbddb9b338d63913f.jpg, createdBy=d1c85308255, createdName=陈弦, createdTime=Sat Oct 09 11:34:38 CST 2021, time=2021-10-09, status=1, ipAttribution=)]
    2021-10-11 amy0550

    #免疫抑制剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1986153, encodeId=1eb319861534b, content=<a href='/topic/show?id=fe4162584ed' target=_blank style='color:#2F92EE;'>#检验指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62584, encryptionId=fe4162584ed, topicName=检验指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jul 07 17:16:38 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852771, encodeId=62dc1852e71fb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Sep 09 14:16:38 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286305, encodeId=072312863056b, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Oct 11 02:16:38 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058972, encodeId=c39910589e29b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73be5472067, createdName=MYR哈哈哈哈, createdTime=Sat Oct 09 15:03:58 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058947, encodeId=bff5105894e27, content=学习了，不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Oct 09 13:20:27 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058909, encodeId=de571058909d9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211110/a1093f9556844f29afef12001f490cf8/3c85211d07a6410dbddb9b338d63913f.jpg, createdBy=d1c85308255, createdName=陈弦, createdTime=Sat Oct 09 11:34:38 CST 2021, time=2021-10-09, status=1, ipAttribution=)]
    2021-10-09 MYR哈哈哈哈

    厉害

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1986153, encodeId=1eb319861534b, content=<a href='/topic/show?id=fe4162584ed' target=_blank style='color:#2F92EE;'>#检验指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62584, encryptionId=fe4162584ed, topicName=检验指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jul 07 17:16:38 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852771, encodeId=62dc1852e71fb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Sep 09 14:16:38 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286305, encodeId=072312863056b, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Oct 11 02:16:38 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058972, encodeId=c39910589e29b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73be5472067, createdName=MYR哈哈哈哈, createdTime=Sat Oct 09 15:03:58 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058947, encodeId=bff5105894e27, content=学习了，不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Oct 09 13:20:27 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058909, encodeId=de571058909d9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211110/a1093f9556844f29afef12001f490cf8/3c85211d07a6410dbddb9b338d63913f.jpg, createdBy=d1c85308255, createdName=陈弦, createdTime=Sat Oct 09 11:34:38 CST 2021, time=2021-10-09, status=1, ipAttribution=)]
    2021-10-09 仁术2021

    学习了，不错

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1986153, encodeId=1eb319861534b, content=<a href='/topic/show?id=fe4162584ed' target=_blank style='color:#2F92EE;'>#检验指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62584, encryptionId=fe4162584ed, topicName=检验指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jul 07 17:16:38 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852771, encodeId=62dc1852e71fb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Sep 09 14:16:38 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286305, encodeId=072312863056b, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Oct 11 02:16:38 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058972, encodeId=c39910589e29b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73be5472067, createdName=MYR哈哈哈哈, createdTime=Sat Oct 09 15:03:58 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058947, encodeId=bff5105894e27, content=学习了，不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Oct 09 13:20:27 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058909, encodeId=de571058909d9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211110/a1093f9556844f29afef12001f490cf8/3c85211d07a6410dbddb9b338d63913f.jpg, createdBy=d1c85308255, createdName=陈弦, createdTime=Sat Oct 09 11:34:38 CST 2021, time=2021-10-09, status=1, ipAttribution=)]
    2021-10-09 陈弦

    好

    0

相关资讯

AJRCCM：补体系统与肺动脉高压，国自然新的研究思路？

肺动脉高压(PH)是一种危及生命的心肺疾病，炎症和免疫已成为关键的早期致病因素。尽管肺动脉高压(PAH)的促炎过程是广泛研究的焦点，但其启动机制仍不清楚。

Cell Host & Microbe：脑损伤的早产新生儿的肠道-微生物-免疫-脑轴发育异常 

最近，研究人员分析了60名极度早产婴儿的肠道微生物群、免疫学和神经生理学发展，这些婴儿接受了包括抗生素和益生菌在内的标准医院护理。

免疫、性激素和环境因素是男女COVID-19发病率和死亡率有差异的决定因素。

由严重急性呼吸综合征病毒2型(SARS-CoV-2)引起的冠状病毒病2019 (COVID-19)已导致全球大流行，造成极高的发病率和死亡率。很少有研究可以证实性别对发病率和死亡率的影响

Nat Med：局部输注HER2特异性CAR-T细胞治疗复发性/难治性中枢神经系统肿瘤儿童和年轻患者的临床研究

CAR-T细胞（嵌合抗原受体T细胞）已被证实对包括胶质母细胞瘤在内的造血系统恶性肿瘤具有临床上的疗效，但目前CAR-T细胞治疗策略在儿童中枢神经系统（CNS）肿瘤中的可行性和耐受性仍有待研究。

CELL：如何通过饮食调节肠道微生物，从而提高免疫力？

最近，研究人员确定了两种以微生物群为目标的饮食干预措施，即植物性纤维和发酵食品，是如何影响健康成年人的体内微生物群和免疫系统。

Cell Metab：为什么越老越怕冷？免疫细胞来“背锅”。

IL-33会促进致病的ILC2s增殖，这些ILC2s有内在的缺陷，会促进促炎症反应和降低脂肪组织的恢复能力，而移植成年ILC2s则足以保护老年小鼠免受寒冷。